Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | BCHE | P06276 | 13/20 | 0.35 |
| ▸ | ACHE | P22303 | 9/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226141 | 0.89 | SIGMAR1 (0.39) | MAOASIGMAR1BCHEACHEMPO | |
| SCHEMBL5226351 | 0.80 | MPO (0.40) | MPOHAVCR2 | |
| Hydrochloric Acid SCHEMBL5412040 | 0.80 | MPO (0.40) | MPOHAVCR2 | |
| SCHEMBL5318072 | 0.78 | MAOA (0.37) | MAOASIGMAR1BCHEACHE | |
| SCHEMBL5452569 | 0.78 | NR1H2 (0.34) | SIGMAR1BCHEACHE | |
| SCHEMBL5333498 | 0.75 | MPO (0.44) | SIGMAR1MPOHAVCR2 | |
| SCHEMBL5230537 | 0.72 | MPO (0.42) | MPO | |
| SCHEMBL5333461 | 0.70 | MAOA (0.46) | MAOA | |
| SCHEMBL5334632 | 0.70 | CDK4 (0.44) | MAOAACHE | |
| SCHEMBL5421563 | 0.69 | SIGMAR1 (0.38) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556387-B1 | SUBSTITUTED BENZOL E| 1,4| OXAZINO 3,2-G| ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2007-04-04 | — | — | EP | claimed |
| US-7312213-B2 | Substituted benzo[e][1,4]oxazino[3,2-g]isoindole compounds | LES LABORATORIES SERVIER (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1556387-B1 | SUBSTITUTED BENZOL E| 1,4| OXAZINO 3,2-G| ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2007-04-04 | — | — | EP | disclosed |
| US-20060003997-A1 | Substituted benzo[e] [1,4] oxazino [3,2-g] isoindole compounds | LES LABORATOIRES SERVIER (FR) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003997-A1 | Substituted benzo[e] [1,4] oxazino [3,2-g] isoindole compounds | H1-3, H1-0, H1-2 | MAOA 889/4885SIGMAR1 210/4885BCHE 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.